SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A. Patel, G. S. Sayuk, C. P. Gyawali, Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring, Neurogastroenterology & Motility, 2016, 28, 5
  2. 2
    C. Prakash Gyawali, Redeeming Clinical Value of Esophageal pH Impedance Monitoring, Clinical Gastroenterology and Hepatology, 2016, 14, 1, 47

    CrossRef

  3. 3
    Rishi D Naik, Michael F Vaezi, Extra-esophageal gastroesophageal reflux disease and asthma: understanding this interplay, Expert Review of Gastroenterology & Hepatology, 2015, 9, 7, 969

    CrossRef

  4. 4
    Motoyasu Kusano, Hiroko Hosaka, Osamu Kawamura, Akiyo Kawada, Shiko Kuribayashi, Yasuyuki Shimoyama, Hidetoshi Yasuoka, Masafumi Mizuide, Taku Tomizawa, Toshihiko Sagawa, Ken Sato, Masanobu Yamada, More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy, Journal of Gastroenterology, 2015, 50, 3, 298

    CrossRef

  5. 5
    T. V. K. Herregods, M. Troelstra, P. W. Weijenborg, A. J. Bredenoord, A. J. P. M. Smout, Patients with refractory reflux symptoms often do not have GERD, Neurogastroenterology & Motility, 2015, 27, 9
  6. 6
    J. Tack, F. Zerbib, K. Blondeau, S. B. Varannes, H. Piessevaux, J. Borovicka, F. Mion, M. Fox, A. J. Bredenoord, H. Louis, S. Dedrie, M. Hoppenbrouwers, A. Meulemans, A. Rykx, L. Thielemans, M. Ruth, Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment, Neurogastroenterology & Motility, 2015, 27, 2
  7. 7
    Akihito Nagahara, Mariko Hojo, Daisuke Asaoka, Hitoshi Sasaki, Sumio Watanabe, A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan, Scandinavian Journal of Gastroenterology, 2014, 49, 4, 409

    CrossRef

  8. You have free access to this content8
    M. R. Ostovaneh, B. Saeidi, K. Hajifathalian, Y. Farrokhi-Khajeh-Pasha, A. Fotouhi, S. S. Mirbagheri, H. Emami, G. Barzin, S. A. Mirbagheri, Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial, Neurogastroenterology & Motility, 2014, 26, 5
  9. 9
    Arne Kandulski, Peter Malfertheiner, Helicobacter pylori and gastroesophageal reflux disease, Current Opinion in Gastroenterology, 2014, 30, 4, 402

    CrossRef

  10. 10
    P. Woodland, D. Sifrim, Oesophageal mucosal barrier: a key factor in the pathophysiology of non-erosive reflux disease (NERD) and a potential target for treatment, Gut, 2014, 63, 5, 705

    CrossRef

  11. 11
    N. Bortoli, I. Martinucci, E. Savarino, M. Bellini, A. J. Bredenoord, R. Franchi, L. Bertani, M. Furnari, V. Savarino, C. Blandizzi, S. Marchi, Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?, Neurogastroenterology & Motility, 2014, 26, 1
  12. 12
    Simon Nennstiel, Monther Bajbouj, Roland M Schmid, Valentin Becker, Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case series, Journal of Medical Case Reports, 2014, 8, 1, 34

    CrossRef

  13. 13
    Jae Hoon Yang, Ho Suk Kang, Sun-Young Lee, Jeong Hwan Kim, In-Kyung Sung, Hyung Seok Park, Chan Sup Shim, Choon Jo Jin, Recurrence of gastroesophageal reflux disease correlated with a short dinner-to-bedtime interval, Journal of Gastroenterology and Hepatology, 2014, 29, 4
  14. 14
    F. Cremonini, Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials, Neurogastroenterology & Motility, 2014, 26, 7
  15. 15
    David S. Estores, Symptom Predictability in Gastroesophageal Reflux Disease and Role of Proton Pump Inhibitor Test, Gastroenterology Clinics of North America, 2014, 43, 1, 27

    CrossRef

  16. 16
    Edoardo Savarino, Chiara De Cassan, Giorgia Bodini, Manuele Furnari, Nicola de Bortoli, Vincenzo Savarino, The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders, Journal of Gastroenterology, 2014, 49, 9, 1362

    CrossRef

  17. 17
    Philip Woodland, Chung Lee, Yasotha Duraysami, Ricard Farré, Peter Dettmar, Daniel Sifrim, Assessment and Protection of Esophageal Mucosal Integrity in Patients With Heartburn Without Esophagitis, The American Journal of Gastroenterology, 2013, 108, 4, 535

    CrossRef

  18. 18
    A. J. Bredenoord, A. J. P. M. Smout, Association between reflux and symptoms during ambulatory reflux monitoring: pros and cons of existing methods, Neurogastroenterology & Motility, 2013, 25, 8
  19. 19
    Ji Yeon Kim, Nayoung Kim, Pyoung Ju Seo, Jung Won Lee, Min Soo Kim, Sung Eun Kim, So Young Jo, Dong Ho Lee, Hyun Chae Jung, Association of Sleep Dysfunction and Emotional Status With Gastroesophageal Reflux Disease in Korea, Journal of Neurogastroenterology and Motility, 2013, 19, 3, 344

    CrossRef

  20. 20
    S. Parasa, P. Sharma, Complications of gastro-oesophageal reflux disease, Best Practice & Research Clinical Gastroenterology, 2013, 27, 3, 433

    CrossRef

  21. 21
    Albert J Bredenoord, John E Pandolfino, André JPM Smout, Gastro-oesophageal reflux disease, The Lancet, 2013, 381, 9881, 1933

    CrossRef

  22. 22
    Arne Kandulski, Ulrich Peitz, Klaus Mönkemüller, Helmut Neumann, Jochen Weigt, Peter Malfertheiner, GERD assessment including pH metry predicts a high response rate to PPI standard therapy, BMC Gastroenterology, 2013, 13, 1, 12

    CrossRef

  23. You have free access to this content23
    A. Kandulski, D. Jechorek, C. Caro, J. Weigt, T. Wex, K. Mönkemüller, P. Malfertheiner, Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn, Alimentary Pharmacology & Therapeutics, 2013, 38, 6
  24. You have free access to this content24
    M. S. Wu, S. C. Tan, T. Xiong, Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease, Alimentary Pharmacology & Therapeutics, 2013, 38, 2
  25. 25
    Philip Woodland, Daniel Sifrim, Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors, Current Opinion in Gastroenterology, 2013, 29, 4, 431

    CrossRef

  26. 26
    A. Kandulski, P. Malfertheiner, J. Weigt, Moderne Funktionsdiagnostik bei Ösophaguserkrankungen, Der Internist, 2013, 54, 3, 279

    CrossRef

  27. 27
    Edoardo Savarino, Patrizia Zentilin, Vincenzo Savarino, NERD: an umbrella term including heterogeneous subpopulations, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 6, 371

    CrossRef

  28. 28
    Edoardo Savarino, Patrizia Zentilin, Vincenzo Savarino, Non-Erosive Reflux Disease is More Complex Than Negative Endoscopy Only, The American Journal of Gastroenterology, 2013, 108, 10, 1657

    CrossRef

  29. 29
    Andrew J. Gawron, John E. Pandolfino, Scott Miskevics, Sherri L. LaVela, Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease, Journal of General Internal Medicine, 2013, 28, 7, 930

    CrossRef

  30. 30
    Marcelo F Vela, Lauren B Gerson, Philip O Katz, Response to Savarino et al., The American Journal of Gastroenterology, 2013, 108, 10, 1658

    CrossRef

  31. 31
    E. Savarino, P. Zentilin, V. Savarino, It is time to plan clinical trials on true NERD patients, Neurogastroenterology & Motility, 2012, 24, 9
  32. 32
    C. Scarpignato, Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!, Neurogastroenterology & Motility, 2012, 24, 8
  33. 33
    P. W. Weijenborg, F. Cremonini, A. J. P. M. Smout, A. J. Bredenoord, Response to letter ‘It is time to plan clinical trials on true NERD patients’, Neurogastroenterology & Motility, 2012, 24, 9
  34. 34
    Arne Kandulski, Marino Venerito, Peter Malfertheiner, Helicobacter pylori and esophageal neoplasia,